Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M637Revenue $M102Net Margin (%)-107.9Altman Z-Score-10.8
Enterprise Value $M701EPS $-1.0Operating Margin %-90.4Piotroski F-Score1
P/E(ttm)--Beneish M-Score-1.5Pre-tax Margin (%)-107.3Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.7Cash flow > EarningsN
Price/Sales5.95-y EBITDA Growth Rate %--Current Ratio0.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-80.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M116ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with MACK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MACKJoel Greenblatt 2015-06-30 Sold Out $10.76 - $13.67
($12.09)
$ 5.51-54%Sold Out0
MACKJoel Greenblatt 2015-03-31 Buy $8.78 - $12.48
($10.82)
$ 5.51-49%New holding13,433
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MACK is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


MACK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stewart Edward J.Head of Commercial 2016-01-05Sell4,000$8-32.25view
Stewart Edward J.Head of Commercial 2015-12-01Sell5,000$9.33-41.91view
Stewart Edward J.Head of Commercial 2015-11-02Sell6,000$9.42-42.46view
Stewart Edward J.Head of Commercial 2015-10-16Sell1,000$10-45.8view
Stewart Edward J.Head of Commercial 2015-10-02Sell5,000$8.2-33.9view
Stewart Edward J.Head of Commercial 2015-09-01Sell6,000$9.88-45.14view
PORTER MICHAEL EDirector 2015-08-21Buy5,000$9.76-44.47view
Stewart Edward J.Head of Commercial 2015-08-17Sell6,000$10.49-48.33view
PORTER MICHAEL EDirector 2015-08-14Buy13,000$10.54-48.58view
Dineen John M.Director 2015-08-12Buy100,000$10.15-46.6view

Quarterly/Annual Reports about MACK:

    News about MACK:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Starbucks Corp, KD Supply Holdings Inc, Capital One Financial Corp, Merr Dec 14 2014 

    More From Other Websites
    Merrimack CEO: Face of pharma isn't a bad actor Feb 04 2016
    Merrimack Reports Positive Onivyde Data in Pancreatic Cancer Jan 20 2016
    Updated Data Shows ONIVYDE® (irinotecan liposome injection) Combination Regimen Increased One Year... Jan 19 2016
    3 Biotech Stocks Under $10 to Trade for Big Breakouts Jan 13 2016
    Merrimack to Present Updated Overall Survival Analysis of Phase 3 NAPOLI-1 Study of ONIVYDE™... Jan 11 2016
    Merrimack to Present Updated Overall Survival Analysis of Phase 3 NAPOLI-1 Study of ONIVYDE™... Jan 11 2016
    Merrimack to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 05 2016
    Merrimack to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 05 2016
    A Refreshing Outlook - Research Reports on Cobalt International Energy, Merrimack Pharmaceuticals,... Dec 29 2015
    Merrimack Alters Endpoint in Cancer Drug Trial, Raises Funds Dec 23 2015
    Merrimack Announces Private Placement of $175 Million of Senior Secured Notes Dec 22 2015
    Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to... Dec 22 2015
    MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 22 2015
    Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to... Dec 22 2015
    Merrimack Announces Private Placement of $175 Million of Senior Secured Notes Dec 22 2015
    Merrimack Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 14 2015
    Do Hedge Funds Love Merrimack Pharmaceuticals Inc (MACK)? Dec 13 2015
    Do Hedge Funds Love Ollie’s Bargain Outlet Holdings Inc (OLLI)? Dec 12 2015
    MERRIMACK PHARMACEUTICALS INC Financials Dec 08 2015
    Merrimack Announces Presentations at the 2015 San Antonio Breast Cancer Symposium Dec 04 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK